Form 4: Bicara Therapeutics CMO Granted 100,000 Stock Options

Bicara Therapeutics' Chief Medical Officer, David Raben, received a grant of 100,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Summary

• David Raben, Chief Medical Officer of Bicara Therapeutics Inc. (BCAX), was granted 100,000 stock options.
• The transaction date for this grant was February 2, 2026.
• Each stock option has an exercise price of $16.76.
• The options will vest in sixteen equal quarterly installments following February 2, 2026, contingent on Mr. Raben's continued service.
• The expiration date for these stock options is February 2, 2036.
• Following this transaction, Mr. Raben beneficially owns 100,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive, as it represents a standard executive compensation practice that aligns management's interests with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of executive compensation designed to attract and retain key talent.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market price of Bicara Therapeutics Inc. common stock exceeding the $16.76 exercise price.
• The options are subject to forfeiture if the reporting person's service to the company ceases before the vesting schedule is complete.
• Potential dilution of existing shareholder equity if and when the options are exercised.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity compensation.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Medical Officer is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is widely used to incentivize long-term commitment and align executive performance with shareholder value creation, particularly in companies with significant research and development cycles like Bicara Therapeutics.

Comparison to Industry Standards

• Executive equity grants, such as the 100,000 stock options granted to Bicara Therapeutics' CMO, are a standard component of compensation packages across the biotech sector, comparable to practices at companies like Moderna or BioNTech, which frequently use stock-based incentives to retain scientific and medical leadership.
• The vesting schedule of sixteen equal quarterly installments over four years is a typical structure designed to encourage long-term retention and performance, aligning with common industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased alignment of executive incentives with company performance.
• Executive (David Raben): Receives significant long-term incentive compensation tied to the company's stock performance and continued service.

Next Steps

• The stock options will continue to vest in sixteen equal quarterly installments following February 2, 2026, subject to the Chief Medical Officer's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Stock Options, Executive Compensation, Insider Transaction, Form 4, Chief Medical Officer, Equity Grant